12 results
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:11pm
and the field’s focus for immunotherapy development. While PD-1 inhibitors have revolutionized cancer therapy, still only a minority of patients respond
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
8:08am
but are effective in only a minority of patients. Additional overall survival gains must come from novel combinations that more broadly target the cancer
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
7:09am
. Existing marketed PD-1’s transformed the treatment of cancer
over the past decade but are effective in only a minority of patients. Additional
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
it as a next-generation PD-1. Existing marketed PD-1’s transformed the treatment of cancer
over the past decade but are effective in only a minority
8-K
EX-10.1
CHRS
Coherus Biosciences Inc
7 Jan 22
Coherus BioSciences Secures Credit Financing
8:36am
) prohibitions or limitations imposed by any Loan Document;
(n) customary provisions set forth in joint venture agreements or agreements governing minority … applies only to the joint venture entity or minority investment that is the subject of such agreement;
(o) limitations imposed with respect to any
8-K
EX-10.1
p1nwh2x6zkq
11 Jan 19
Entry into a Material Definitive Agreement
4:08pm
10-K
f1404kqaisz xqbva9
23 Mar 15
Annual report
12:00am
424B4
uodvvt8 a1u9ny4
6 Nov 14
Prospectus supplement with pricing info
12:00am
S-1/A
dw2esdmeimpq7slvx7ne
6 Oct 14
IPO registration (amended)
12:00am
DRS/A
w36s6d3 fhz6lszbfmen
15 Sep 14
Draft registration statement (amended)
12:00am
DRS
xa231
4 Aug 14
Draft registration statement
12:00am
- Prev
- 1
- Next